



## **Idera Pharmaceuticals Provides Update on Its Patent Portfolio**

August 9, 2011 12:17 PM EDT

### **- Achieves Top Impact Score and 12<sup>th</sup> Consecutive Top 35 Ranking by the Patent Board(TM)**

CAMBRIDGE, Mass., Aug 09, 2011 (BUSINESS WIRE) --

Idera Pharmaceuticals, Inc. (Nasdaq: IDRA) today provided an update on its intellectual property portfolio. The Company's intellectual property portfolio now contains over 575 issued patents and pending patent applications covering compositions of matter and methods of use for Idera's technologies that include TLR-targeted immune modulatory oligonucleotides (IMO), gene silencing oligonucleotide (GSO) technology, and antisense technology. The Company also announced that it recently received the Patent Board's top impact score and that it was recognized for the 12<sup>th</sup> consecutive time over the past four years by the Patent Board(TM) as one of the top 35 companies in the biotechnology field based on its technology and intellectual property strength.

"The compounds claimed in our issued patents were created in-house using our nucleic acid chemistry expertise, and we are pleased that patent offices around the world continue to recognize the novelty, utility, and the diverse application of our technologies," commented Steven Ritter, Ph.D., J.D., Vice President of Intellectual Property and Contracts. "We believe achieving the top impact score and continuous top 35 ranking by the Patent Board is an independent affirmation of the strength of our science and intellectual property."

The Company's most recently issued U.S. patents include:

- US 7,812,000, entitled "Modulation of immunostimulatory properties of oligonucleotide-based compounds by optimal presentation of 5' ends"
- US 7,833,538, US 7,824,696, and US 7,932,367, entitled "Modulation of immunostimulatory activity of immunostimulatory oligonucleotide analogs by positional chemical changes"
- US 7,851,453 and US 7,863,250, entitled "Modulation of immunostimulatory properties of oligonucleotide-based compounds by utilizing modified immunostimulatory dinucleotides"
- US 7,851,454, entitled "Short immunomodulatory oligonucleotides"
- US 7,875,594, entitled "Synergistic treatment of cancer using immunomers in conjunction with chemotherapeutic agents"
- US 7,884,197 and US 7,960,362, entitled "Synthetic agonists of TLR9"

In addition to the issued U.S. patents, a patent corresponding to US 6,426,334 was granted in Canada, France, Germany, and Great Britain; a patent corresponding to US 6,476,000 was granted in Mexico; a patent corresponding to US 20050026861 was granted in Australia and Mexico; and a patent corresponding to US 7,427,405 was issued in Australia.

#### **About Idera Pharmaceuticals' Intellectual Property Portfolio**

Idera's intellectual property portfolio contains over 575 issued patents and pending patent applications in countries around the world.

##### **Immune Modulatory Oligonucleotides (IMO(R))**

Idera's IMO intellectual property portfolio contains over 315 patents and patent applications in countries around the world owned by Idera and covering its IMO technologies and includes claims covering novel agonists of TLRs 3, 7, 8, and 9 and antagonists of TLRs 7 and 9. These patents and patent applications also include claims covering IMO-2055, IMO-2125, IMO-2134, IMO-3100, and IMO-4200.

##### **Gene Silencing Oligonucleotide (GSO) Technology**

Idera's GSO intellectual property portfolio contains five patent applications in countries around the world owned by Idera and covering its GSO technology. GSOs are single-stranded RNA or DNA constructs, with two exposed 3'-ends, that are complementary to targeted mRNA or miRNA sequences of therapeutic interest.

##### **Antisense Technology**

Idera's antisense intellectual property portfolio contains over 255 patents and patent applications in countries around the world owned or licensed by Idera and covering novel antisense compositions and methods of their use. These patents and patent applications include claims covering second-generation antisense chemistry, oral delivery of second-generation antisense compounds, and antisense compounds for certain therapeutic targets.

#### **About the Patent Board(TM)**

The Patent Board(TM) is an independent group that tracks and analyzes intellectual property and technology assets across 17 industries globally and publishes its results in the *Wall Street Journal*.

#### **About Idera Pharmaceuticals, Inc.**

Idera Pharmaceuticals develops drug candidates to treat infectious diseases, autoimmune and inflammatory diseases, cancer, and respiratory

diseases, and for use as vaccine adjuvants. Our proprietary drug candidates are designed to modulate specific Toll-like Receptors, which are a family of immune system receptors that direct immune system responses. Our pioneering DNA and RNA chemistry expertise enables us to create drug candidates for internal development and generates opportunities for multiple collaborative alliances. For more information, visit [www.iderapharma.com](http://www.iderapharma.com).

#### **Idera Forward Looking Statements**

This press release contains forward-looking statements concerning Idera Pharmaceuticals, Inc. that involve a number of risks and uncertainties. For this purpose, any statements contained herein that are not statements of historical fact may be deemed to be forward-looking statements. Without limiting the foregoing, the words "believes," "anticipates," "plans," "expects," "estimates," "intends," "should," "could," "will," "may," and similar expressions are intended to identify forward-looking statements. There are a number of important factors that could cause Idera's actual results to differ materially from those indicated by such forward-looking statements, including the impact of our strategic review on our plans for the development of our drug candidates and technologies; whether results obtained in preclinical studies and early clinical trials will be indicative of results obtained in future clinical trials; whether products based on Idera's technology will advance into or through the clinical trial process on a timely basis or at all and receive approval from the United States Food and Drug Administration or equivalent foreign regulatory agencies; whether, if the Company's products receive approval, they will be successfully distributed and marketed; whether the Company's collaborations with Merck KGaA and Merck & Co, Inc., will be successful; whether the patents and patent applications owned or licensed by the Company, such as the patents and patent applications referred to on this release, will protect the Company's technology and prevent others from infringing it; whether Idera's cash resources will be sufficient to fund the Company's operations; and such other important factors as are set forth under the caption "Risk Factors" in Idera's Quarterly Report on Form 10-Q for the quarter ended June 30, 2011 which important factors are incorporated herein by reference. Idera disclaims any intention or obligation to update any forward-looking statements.

SOURCE: Idera Pharmaceuticals, Inc.

Idera Pharmaceuticals, Inc.

Lou Arcudi, 617-679-5517

[larcudi@iderapharma.com](mailto:larcudi@iderapharma.com)

or

MacDougall Biomedical Communications

Chris Erdman, 781-235-3060

[cerdman@macbiocom.com](mailto:cerdman@macbiocom.com)